.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
Novartis
Medtronic
Teva
Express Scripts
Cerilliant
Cipla
Boehringer Ingelheim
Citi

Generated: December 13, 2017

DrugPatentWatch Database Preview

NICODERM CQ Drug Profile

« Back to Dashboard

Which patents cover Nicoderm Cq, and what generic alternatives are available?

Nicoderm Cq is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty-three countries.

The generic ingredient in NICODERM CQ is nicotine. There are twenty-nine drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the nicotine profile page.
Drug patent expirations by year for NICODERM CQ

Medical Subject Heading (MeSH) Categories for NICODERM CQ

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-006Aug 2, 1996OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-006Aug 2, 1996OTCYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-004Aug 2, 1996OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996OTCYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-006Aug 2, 1996OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-006Aug 2, 1996OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-004Aug 2, 1996OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NICODERM CQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-006Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-004Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-006Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-004Aug 2, 1996► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-004Aug 2, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NICODERM CQ

Drugname Dosage Strength RLD Submissiondate
nicotineTransdermal System7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrsNicoderm CQ5/30/2014

Non-Orange Book Patents for Tradename: NICODERM CQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,622,136Transparent transdermal nicotine delivery devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NICODERM CQ

Country Document Number Estimated Expiration
Hong Kong1040915► Subscribe
Norway332084► Subscribe
China101693023► Subscribe
New Zealand512432► Subscribe
Russian Federation2246937► Subscribe
Canada2354621► Subscribe
Germany69941629► Subscribe
Denmark1140039► Subscribe
Poland195871► Subscribe
Japan4864204► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Medtronic
Chinese Patent Office
Moodys
Cantor Fitzgerald
Farmers Insurance
Baxter
Queensland Health
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot